(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller ...

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...

I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.

The Food & Drug Administration granted AbbVie expanded approval for its Rinvoq drug intended to treat moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ...

The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn ...

AbbVie's strong results, pipeline wins, and Rinvoq exclusivity boost its outlook. Read the latest analysis on ABBV stock here.

Rinvoq is the first oral drug for moderate to severe Crohn’s disease — a chronic intestinal disorder — to be approved by the Food and Drug Administration. There is no cure for Crohn’s disease, and the ...

Rinvoq (upadacitinib) is a brand-name tablet that’s prescribed for rheumatoid arthritis and certain other conditions. The cost of the drug with and without insurance can depend on several factors, ...

AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira in a ...